NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - General · USD

Amarin Corporation plc (AMRN) Stock Analysis

Amarin Corporation plc (AMRN) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AMRN

$11.51

+$0.03 (+0.26%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AMRN with… →

AMRN Key Statistics

As of Oct 21, 2026
Trading
Open
$11.60
Previous Close
$11.48
Day's Range
11.46–11.67
52-Week Range
11.25–20.90
Volume
37.94K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.77
Valuation
Market Cap
$243.12M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
11.74
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.81
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
1.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.20
Financials (FY)
Revenue (FY)
$213.65M−6.55%
Net Income (FY)
−$38.80M
Profit marginThe share of revenue left as profit after all costs and taxes.
−14.57%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
21.12M
1-Year Return
−42.28%
Dividend and dates
Earnings Date
October 28, 2026
Avg Volume
66.34K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AMRN closed at $11.51, −42.28% over 1 year.

Amarin Corporation plc (AMRN) has a market capitalization of $243.12M.

In fiscal 2025, AMRN reported revenue of $213.65M.

AMRN Stock Return by Calendar Year

Amarin Corporation plc (AMRN) 10-year return: what $10,000 became

1 year
$10,000 $5,772
−42.28%
5 years
$10,000 $1,149
−88.51%
10 years
$10,000 $1,798
−82.02%

If you had invested $10,000 in Amarin Corporation plc (AMRN) 10 years ago, at the close on October 21, 2016, it would have been worth $1,798 at the close on October 21, 2026: −82.02% in total, −15.77% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−17.55%
2025+42.45%
2024−43.68%
2023−28.10%
2022−64.09%
2021−31.08%
2020−77.19%
2019+57.53%
2018+239.40%
2017+30.19%
2016 (partial year)−3.45%

As of October 21, 2026.

AMRN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$213.65M−$38.80M−18.2%
2024$228.61M−$82.18M−35.9%
2023$306.91M−$59.11M−19.3%
2022$369.19M−$105.80M−28.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$213.65M$120.87M−$13.94M−$38.80M−18.2%
2024$228.61M$81.38M−$91.80M−$82.18M−35.9%
2023$306.91M$165.54M−$56.62M−$59.11M−19.3%
2022$369.19M$242.48M−$92.34M−$105.80M−28.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AMRN Valuation vs Drug Manufacturers - General Median

Median of 21 stocks
MetricAMRNDrug Manufacturers - General medianvs median
P/S ratio1.313.2360% below
Profit margin−14.57%9.80%24.4 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Amarin Corporation plc (AMRN) is capitalised at $243.12M on the latest close. It is classified in the Drug Manufacturers - General industry, within the Healthcare sector. The company reports 80 employees.

The 52-week range on file runs from $11.25 to $20.90. The most recent close on file for AMRN is $11.51, dated October 21, 2026. That is +$0.03 (+0.26%) against the previous close. The latest close sits 2.31% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $213.65M. Against the prior fiscal year total of $228.61M, that is a change of −6.55%. The same year closed with a net loss of $38.80M. The reported profit margin is −14.57%. That is 24.4 percentage points below the Drug Manufacturers - General median of 9.8%. Trailing earnings per share are −1.2.

Across the 4 fiscal years on file, revenue moves from $369.19M in 2022 to $213.65M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 11.74. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.81. Measured against sales, the shares trade at 1.31 times revenue. On price-to-sales that is 59.57% below the Drug Manufacturers - General median of 3.23. The medians here are taken across 21 Drug Manufacturers - General companies that report the metric.

Beta against the wider market is reported at 0.77. Daily returns over the trailing 10 years annualize to a volatility of 121.41%. Over the trailing twelve months the total return is −42.28%. Measured over 10 years, that is −15.77% a year compounded.

Growth & Income

No dividend is on file for AMRN.

Across the complete calendar years on file, 2018 returned +239.40% and 2020 returned −77.19%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the total return is −17.55%.

Peer Comparison

Amarin Corporation plc (AMRN) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Amarin Corporation plc AMRN $243.12M —
Eli Lilly and Company LLY $1.13T 42.7
Johnson & Johnson JNJ $621.22B 39.1
AbbVie Inc. ABBV $503.27B 80.5

The Drug Manufacturers - General industry average P/E ratio is 25.2x. Amarin Corporation plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 MRK

Merck & Co., Inc.

$369.78B

 NVS

Novartis AG

$292.58B

 AZN

AstraZeneca PLC

$261.82B
View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$374.30B

 TMO

Thermo Fisher Scientific Inc.

$256.61B

 AMGN

Amgen Inc.

$236.98B

 GILD

Gilead Sciences, Inc.

$190.42B

 ABT

Abbott Laboratories

$173.92B
View all Healthcare stocks →

About Amarin Corporation plc

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, EPA. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Visit website →